Skip to content
sellModerate cluster of 1110b5-1 plan

Elizabeth L Hougen sold $16M of IONS

EVP, Finance & CFO at IONIS PHARMACEUTICALS INC. 225,220 shares at an average of $72.43, traded Mar 16, 2026, filed Mar 18, 2026.

Warning score
47
Value
$16M
225,220 shares
Holdings after
82,660
-73% from before
From 52-week low
+184%
low $25.51, close $72.34
From 52-week high
-16%
high $86.50, as of Mar 16, 2026

Score components

  • Role
    CFO
    +22
  • Trade size
    $16.3M at market
    +25
  • Share of holdings sold
    Sold 73% of holdings
    +20
  • Cluster
    11 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +5.6%, 3m +3.7%, 6m -37.4%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

IONSOct 9, 2026 · close 45.28
Since filing Mar 18, 2026: -36.8%SPY +18.6% · excess -55.5%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000874015-26-000146, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 16, 2026MOption exercise
Common Stock10b5-1
+60,299$60.89$3.7M193,180Mar 18, 2026
Mar 16, 2026MOption exercise
Common Stock10b5-1
+61,041$56.78$3.5M254,221Mar 18, 2026
Mar 16, 2026MOption exercise
Common Stock10b5-1
+33,118$32.60$1.1M287,339Mar 18, 2026
Mar 16, 2026MOption exercise
Common Stock10b5-1
+20,541$37.58$772k307,880Mar 18, 2026
Mar 16, 2026SOpen-market sale
Common Stock10b5-1
-205,608$72.38$15M102,272Mar 18, 2026
Mar 16, 2026SOpen-market sale
Common Stock10b5-1
-9,440$72.77$687k92,832Mar 18, 2026
Mar 17, 2026SOpen-market sale
Common Stock10b5-1
-10,172$73.21$745k82,660Mar 18, 2026
Mar 16, 2026MOption exercise
Non-Qualified Stock Option (right to buy)derivative10b5-1
-33,118$0.00$00Mar 18, 2026
Mar 16, 2026MOption exercise
Non-Qualified Stock Option (right to buy)derivative10b5-1
-20,541$0.00$05,405Mar 18, 2026
Mar 16, 2026MOption exercise
Non-Qualified Stock Option (right to buy)derivative10b5-1
-61,041$0.00$00Mar 18, 2026
Mar 16, 2026MOption exercise
Non-Qualified Stock Option (right to buy)derivative10b5-1
-60,299$0.00$00Mar 18, 2026

Related signals

Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
58Moderate
IONSbuy
IONIS PHARMACEUTICALS INC
Michael R Hayden
director
$1.1M
20,000 shares
+500%
45Moderate
IONSsell 910b5-1
IONIS PHARMACEUTICALS INC
C Frank Bennett
EVP, Chief Scientific Officer
$1.7M
20,536 shares
-25%
38Weak
IONSsell 910b5-1
IONIS PHARMACEUTICALS INC
Allene M. Diaz
director
$864k
10,111 shares
-73%
15Weak
IONSsell 910b5-1
IONIS PHARMACEUTICALS INC
Holly B. Kordasiewicz
EVP, Chief Development Officer
$31k
362 shares
-2%
39Weak
IONSsell 910b5-1
IONIS PHARMACEUTICALS INC
Joseph Klein III
director
$910k
11,518 shares
-51%
32Weak
IONSsell 1010b5-1
IONIS PHARMACEUTICALS INC
Joseph Baroldi
EVP, Chief Business Officer
$452k
5,635 shares
-55%
30Weak
IONSsell 1010b5-1
IONIS PHARMACEUTICALS INC
Eugene Schneider
EVP, Chf Clinical Develop Ofcr
$2.1M
26,000 shares
-25%
23Weak
IONSsell 1010b5-1
IONIS PHARMACEUTICALS INC
Patrick R. O'Neil
EVP CLO & General Counsel
$246k
3,069 shares
-5%
43Moderate
IONSsell 1010b5-1
IONIS PHARMACEUTICALS INC
Eric Swayze
EVP Research
$839k
10,602 shares
-33%
40Moderate
IONSsell 1010b5-1
IONIS PHARMACEUTICALS INC
Brett P Monia
Chief Executive Officer
$6.8M
85,637 shares
-33%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Elizabeth L Hougen sold $16M of IONS | InsiderTell